Arcturus Therapeutics Holdings Inc. - San Diego's own late-stage clinical messenger RNA medicines and vaccine company - has its sights set on developing infectious disease vaccines as well as other products for liver and respiratory rare diseases. With robust technology platforms including LUNAR lipid-mediated delivery and STARR mRNA, the company is in the process of developing three different mRNA-based therapeutic candidates. ARCT-810 (LUNAR-OTC), currently in Phase 2 clinical trial, is targeted at treating ornithine transcarbamylase deficiency. ARCT-154 (LUNAR-COV19) is an mRNA vaccine candidate in the Phase 3 arm of a Phase 1/2/3 study being conducted in Vietnam for the treatment of COVID-19. Lastly, ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate, aims to address cystic fibrosis simply via mRNA. Arcturus was founded back in 2013 with the objective of innovating within the medical field through messenger RNA therapeutics and its technology has proven successful in clinical trials to date.
Arcturus Therapeutics's ticker is ARCT
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Arcturus Therapeutics
It is arcturusrx.com
Arcturus Therapeutics is in the Healthcare sector
Arcturus Therapeutics is in the Biotechnology industry
The following five companies are Arcturus Therapeutics's industry peers: